Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Park Avenue Securities LLC

Park Avenue Securities LLC increased its position in Insmed Incorporated (NASDAQ:INSM) by 28.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,597 shares of the biopharmaceutical company’s stock after buying an additional 1,240 shares during the quarter. Park Avenue Securities LLC’s holdings in Insmed were worth $409,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. EntryPoint Capital LLC purchased a new stake in shares of Insmed during the first quarter valued at $33,000. Fidelis Capital Partners LLC purchased a new stake in shares of Insmed during the first quarter valued at $34,000. First Horizon Advisors Inc. lifted its holdings in shares of Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 287 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Insmed during the first quarter valued at $59,000. Finally, CWM LLC lifted its holdings in shares of Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares during the last quarter.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $74.56 on Friday. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The firm has a market cap of $11.08 billion, a price-to-earnings ratio of -14.26 and a beta of 1.11. The business’s 50-day simple moving average is $73.84 and its 200-day simple moving average is $56.80. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. During the same period last year, the firm posted ($1.78) EPS. The firm’s revenue for the quarter was up 17.0% compared to the same quarter last year. As a group, equities research analysts expect that Insmed Incorporated will post -5.41 earnings per share for the current fiscal year.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 78,882 shares of company stock worth $5,765,446 in the last 90 days. 4.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Evercore ISI upped their target price on Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Bank of America upped their price target on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday. Stifel Nicolaus upped their price target on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research report on Friday, August 9th. The Goldman Sachs Group upped their price target on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Finally, Truist Financial upped their price target on Insmed from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.73.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.